Co-Inventors
Weiskopf, Kipp
Weissman, Irving
Stoddart, Cheryl
Therapeutic Areas
Infectious Disease
Immunology
Research Products
Research Equipment
Antibodies
The technology described involves a groundbreaking method for treating intracellular pathogen infections by targeting CD47, a widely expressed transmembrane glycoprotein that acts as a ligand for phagocytic receptors. By administering agents that inhibit CD47 binding to these receptors, the approach enhances the phagocytic removal of infected cells, leading to increased clearance of intracellular pathogens. The inventors demonstrated the effectiveness of this approach in reducing viral infections caused by various intracellular pathogens, including HIV-1 and Chlamydia trachomatis serovar A. Notably, a prior art search suggests that this innovative method is novel, as there is no identified patent or non-patent literature related to the use of CD47 blockade against intracellular pathogens.
Commercial Applications
This technology has diverse potential applications, primarily in treating intracellular pathogen infections like HIV-1 and Chlamydia trachomatis serovar A. Additionally, it may have broader implications in regulating immune responses, potentially offering therapeutic solutions for autoimmune disorders and cancer. Its adaptability across various disease contexts makes it a promising avenue for advancing disease management and immunotherapy.
Competitive Advantages
The technology's competitive advantages lie in its novel approach to intracellular pathogen infection treatment. By specifically targeting CD47, a broadly expressed molecule, it offers versatility and efficacy across a spectrum of intracellular pathogens. The method's potential to enhance phagocytic clearance represents a targeted and efficient treatment strategy. Furthermore, the absence of existing patents or literature on this precise approach underscores its unique and innovative nature, positioning it favorably in the field of infectious disease treatment.
